KRAS and breast carcinoma: U-0126 inhibits anchorage-independent growth of Ki-ras-transformed rat fibroblasts by concurrently suppressing both ERK and mammalian targets of rapamycin (mTOR)-p70(S6K) pathways, and sensitizes human breast cancer MDA-MB-231 and HBC-4 cells to anoikis [52].